Skip to content

Effectivity of using a low-dose UVB lighting solution to maintain healthy vitamin D levels

Using a Low-dose UVB Lighting Solution During Working Hours: An Explorative Investigation Towards the Effectivity in Maintaining Healthy Vitamin D Levels

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN47902923
Enrollment
28
Registered
2021-12-03
Start date
2020-11-23
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D deficiency Nutritional, Metabolic, Endocrine

Interventions

Participants were allocated randomly to the two study conditions as much as possible. This was, however, not possible for several participants as they either changed in their work location or amount o

Sponsors

Signify (Netherlands)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged =18 years 2. Fitzpatrick skin type II or III 3. Living in/around Eindhoven 4. Medically fit to work the hours as contractually agreed 5. Desk presence (at the home office) of at least 2.5 days per week during the 8 weeks study 6. Finding it no problem to have blood drawn three times over a period of 8 weeks

Exclusion criteria

Exclusion criteria: 1. Current pregnancy, breast feeding or a desire to become pregnant 2. Having children at home aged 10 years or younger 3. Having malignant skin conditions in the past or currently 4. Photosensitive medical conditions or photo-sensitising drugs 5. Users of medicines and/or crèmes mentioning in the prescription as side effect extra sensitivity to the sun/interaction with sun exposure 6. Planned use of sun beds, or sunbed use during the past 4 weeks 7. Currently taking or planning to take oral vitamin D3 supplements or have been taking D3 supplements during the past 4 weeks 8. High vitamin D levels at the start of the study (>375 nmol/l) which need medical attention

Design outcomes

Primary

MeasureTime frame
Serum 25(OH)D level measured using blood sampling and automated immunoassay at baseline, 4, and 8 weeks

Secondary

MeasureTime frame
Sleep duration, midsleep timing, sleep quality, and fatigue measured using participant questionnaire at baseline, 4, and 8 weeks

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 9, 2026